The historical rank and industry rank for Doseology Sciences's Net Margin % or its related term are showing as below:
DOSEF'
s Net Margin % Range Over the Past 10 Years
Min: -12118.75 Med: -2593.03 Max: -343.43
Current: -1443.21
DOSEF's Net Margin % is ranked worse than 82.26% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs DOSEF: -1443.21
Doseology Sciences (OTCPK:DOSEF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Doseology Sciences Net Margin % Related Terms
Doseology Sciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Doseology Sciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOSEF vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Doseology Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doseology Sciences Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Doseology Sciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Doseology Sciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Doseology Sciences (DOSEF) has a Net Margin % of -1,605.26% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Doseology Sciences and its competitors. According to the industry distribution chart, Doseology Sciences ranks #779 out of 947 companies in the Biotechnology industry, placing it in the top 82.3%.
Is Doseology Sciences' Net Margin % too high?
Doseology Sciences' current Net Margin % is -1,605.26%. Based on the distribution chart, Doseology Sciences ranks #779 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Doseology Sciences has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Doseology Sciences' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Doseology Sciences ranks #779 out of 947 companies for Net Margin %. This places Doseology Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Doseology Sciences and its competitors. Doseology Sciences's current Net Margin % is -1,605.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doseology Sciences stock overvalued right now?
Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.29, compared to a current price of $0.11 — trading 61.3% below its estimated fair value. The current Net Margin % is -1,605.26%. Doseology Sciences' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current Net Margin % is -1,605.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doseology Sciences (DOSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued.
The current stock price of $0.11 is trading 61.3% below its estimated GF Value™ of $0.29.
GuruFocus considers Doseology Sciences to be Possible Value Trap.
Key valuation signals for DOSEF:
Net Margin %: -1,605.26%
GF Value™: $0.29 vs. price of $0.11 (61.3% below fair value)
No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.
33GF Score
Get the complete analysis for DOSEF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOSEF has been successfully added to your 
